Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet

BACKGROUND: Liraglutide, a GLP‐1 receptor agonist, has recently been used to treat metabolic syndrome (MS) because of its anti‐diabetic and anti‐obesity effects. We have previously shown that Wistar Bonn Kobori diabetic and fatty (WBN/Kob‐Lepr(fa), WBKDF) rats fed a high‐fat diet (HFD) developed MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaji, Noriyuki, Takagi, Yoshiichi, Matsuda, Satomi, Takahashi, Anna, Fujio, Sakurako, Asai, Fumitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167233/
https://www.ncbi.nlm.nih.gov/pubmed/32318661
http://dx.doi.org/10.1002/ame2.12106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167233/
https://www.ncbi.nlm.nih.gov/pubmed/32318661
http://dx.doi.org/10.1002/ame2.12106

Ejemplares similares